Capital increase in Monsenso A/S as a result of warrants exercising of employees

27.9.2023 10:10:58 CEST | Monsenso | Company Announcement

Company announcement no. 14-2023

Copenhagen, 2023.09.27

Monsenso A/S announced today that the Company´s share capital has been increased by nominally DKK 6,221.20 as a result of the exercise of warrant programs.

The capital increase is subscribed in cash at a price per share of DKK 0.22 without pre-emptive rights for the company's existing shareholders or others. The proceeds for the company amount to DKK 13,687. The capital increase corresponds to 0.20 % of the company's previous share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares entitle to dividends and other rights in the company from the time of registration of the capital increase. The new shares will be admitted to listing on Nasdaq First North Growth Market Denmark as soon as possible after registration with the Danish Business Authority.

Monsenso's current share capital amounts to a nominal DKK 3,050,211.10 divided into 30,502,111 shares of DKK 0.10. The capital increase is expected to be completed soon, and after registration the following is expected:

Nominal value of shares DKK	3,056,432.30
Volume of shares (nom. DKK 0.10)	30,564,323

 

Any inquiries regarding this notice should be directed to:

Monsenso

CEO
Thomas Lethenborg
Tel [phone]
E-mail: [e-mail] 

Chairman of the board
Peter Mørch Eriksen
Tel [phone]  
E-mail: [e-mail]

Certified Adviser

Norden CEF A/S
John Norden

E-mail: [e-mail]

About Monsenso

Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com

Attachments

• Download announcement as PDF.pdf

© Ritzau Denmark, source Ritzau English Regulatory Releases